<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15018">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00227370</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00013245</org_study_id>
    <secondary_id>4623 (Val038)</secondary_id>
    <nct_id>NCT00227370</nct_id>
  </id_info>
  <brief_title>Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation</brief_title>
  <acronym>Valgan</acronym>
  <official_title>A Phase III, Randomized, Double-Blind Comparison of Oral Valganciclovir and Placebo for Prevention of CMV After Lung Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scott Palmer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluated the efficacy and safety of a prolonged, continuous course of
      Valganciclovir (Valgan) in the prevention of CMV by comparing 3 months of Vaglanciclovir,
      the standard of care upon initiation of the study, to 12 months of Valganciclovir.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multi-center two phase, double-blind, placebo controlled, randomized prospective study of
      130 lung transplant recipients. Patients will be screened and consented prior to transplant.
      All consented patients will receive IV ganciclovir within 24 hours of transplant for not
      more than 14 days. Patients will enroll in Phase I of the study is an open label safety and
      efficacy analysis of three months of oral valganciclovir in adult transplant recipients who
      are at risk for CMV. After completion of 3 months of open label therapy, patients that meet
      the criteria for Phase II of the study will be randomized to 9 months of blinded therapy
      (Placebo/Valgan). Phase II of the study is designed to assess the efficacy of short course
      sequential IV ganciclovir followed by oral valganciclovir as compared to the extended period
      of oral valganciclovir prophylaxis in the prevention of CMV disease in at risk lung
      transplant recipients
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Incidence of CMV End Organ Disease</measure>
    <time_frame>over the course of 300 days after randomization</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary study end point was CMV end-organ disease determined by positive tissue immunostain or characteristic histopathology assessed for within 300 days post randomization.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of CMV Syndrome</measure>
    <time_frame>over the course of 300 days after randomization</time_frame>
    <safety_issue>No</safety_issue>
    <description>CMV clinical syndrome, with either positive serum PCR or positive culture for CMV from bronchoalveolar lavage and at least 2 of the following: fever, leukopenia, thrombocytopenia, elevated liver function test results malaise, reduction in pulmonary function (FEV1) greater than 20percent of baseline, or radiographic infiltrate consistent with CMV (all in the absence of other causes)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Any CMV Infection</measure>
    <time_frame>over the course of 300 days post randomization</time_frame>
    <safety_issue>No</safety_issue>
    <description>Inclusive of CMV syndrome, disease, or infection not meeting primary end point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biopsy Proven Acute Lung Rejection</measure>
    <time_frame>over the course of 300 days of randomization</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-CMV Infection</measure>
    <time_frame>over the course of 300 days after randomization</time_frame>
    <safety_issue>No</safety_issue>
    <description>non cmv opportunistic infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Viremia</measure>
    <time_frame>over the course of 300 days after randomization</time_frame>
    <safety_issue>No</safety_issue>
    <description>upon diagnosis of cmv disease, the number of CMV DNA copies/mL as measured by PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ganciclovir Resistance</measure>
    <time_frame>over the course of 300 days post randomization</time_frame>
    <safety_issue>No</safety_issue>
    <description>UL97 genotyping was done on all positive samples for CMV DNA at 1000 copies/mL, with resistance defined by the presence of 1 or more mutations shown by marker transfer to confer phenotypic ganciclovir resistance</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">136</enrollment>
  <condition>Cytomegalovirus Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Valganciclovir 900 mg QD for 9 months post lung transplant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo for 9 months post lung transplant</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valganciclovir</intervention_name>
    <description>valgan 900mg QD x 9 months post lung transplant</description>
    <arm_group_label>1</arm_group_label>
    <other_name>valcyte</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Phase I:

          -  Adult lung transplant recipients age 18 or older

          -  At risk for CMV (donor or recipient serology must be positive for CMV)

          -  Adequate hematological and renal function,

          -  On intravenous (IV) ganciclovir within 24 hours of surgery

          -  Agreement to use effective methods of contraception

          -  Negative pregnancy

          -  Tolerate oral medications within 2 weeks of transplant

          -  Negative baseline CMV PCR

          -  Able to understand and sign the informed consent

        Exclusion Criteria for Phase 1:

          -  Repeat transplantation

          -  Mechanical ventilation at study entry

          -  Oral or intravenous ganciclovir treatment outside the study protocol

          -  Invasive fungal infection

          -  Participation in another investigational study

          -  Acute CMV infection or disease

          -  Anti-CMV therapy within 30 days before enrollment

          -  Uncontrolled diarrhea or malabsorption

          -  Allergic reaction to study drug

          -  Required use of prohibited medications

          -  Lactating women

          -  Pregnancy

          -  Renal failure

        Inclusion Criteria for Phase II:

          -  Negative serial post transplant PCRs at day 75

          -  Negative bronchial cultures for CMV

          -  Adequate hematological and renal function at day 75

          -  IV ganciclovir for up to 2 weeks post operation and open label up to day 90

          -  Effective contraceptives

          -  Negative pregnancy

        Exclusion Criteria Phase II:

          -  Renal failure

          -  Serious adverse events (SAE) related to study drug

          -  CMV disease (study endpoint)

          -  Withdraw consent for Phase II
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott M Palmer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DukeUMC</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 25, 2013</lastchanged_date>
  <firstreceived_date>September 26, 2005</firstreceived_date>
  <firstreceived_results_date>January 24, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University Medical Center</investigator_affiliation>
    <investigator_full_name>Scott Palmer</investigator_full_name>
    <investigator_title>Associate Professor of Medicine-Pulmonary</investigator_title>
  </responsible_party>
  <keyword>Acute rejection</keyword>
  <keyword>Non-CMV infections</keyword>
  <keyword>Resistance</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ganciclovir</mesh_term>
    <mesh_term>Valganciclovir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Prospective subjects were screened and enrolled from July 2003 - January 2007 at 11 US lung transplant centers. 189 subjects were screened and 157 met inclusion criteria and were therefore enrolled in the study.</recruitment_details>
      <pre_assignment_details>Upon receipt of a lung transplant, enrolled subjects received 90 days of valganciclovir for CMV prophylaxis, per standard of care, and then were randomly assigned, 1:1, in a double blind fashion, to either the extended prophylaxis group (9 additional months of standard of care dosing Valganciclovir, adjusted for renal function) or placebo group.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo Group</title>
          <description>Upon randomization at 3 months, patients discontinued Valganciclovir and received no CMV prophylaxis for the next 9 months (short course prophylaxis). 3 months of Valganciclovir was the standard of care for CMV prevention at the time of study initiation. This was the prespecified placebo group/intervention arm.</description>
        </group>
        <group group_id="P2">
          <title>Treatment Group</title>
          <description>Upon randomization at 3 months, patients remained on Valganciclovir for 9 additional months (extended course prophylaxis).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="66">Placebo Group</participants>
                <participants group_id="P2" count="70">Treatment Group</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reasons</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo Group</title>
          <description>Upon randomisation at 3 months, patients discontinued Valganciclovir and received no CMV prophylaxis</description>
        </group>
        <group group_id="B2">
          <title>Treatment Group</title>
          <description>Upon randomisation at 3 months, patients remained on Valganciclovir for 9 additional months.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="66"/>
                <measurement group_id="B2" value="70"/>
                <measurement group_id="B3" value="136"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <sub_title>Age</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="50.6" spread="13.8"/>
                <measurement group_id="B2" value="51.9" spread="12.2"/>
                <measurement group_id="B3" value="51.3" spread="13.0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="28"/>
                <measurement group_id="B2" value="41"/>
                <measurement group_id="B3" value="69"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="38"/>
                <measurement group_id="B2" value="29"/>
                <measurement group_id="B3" value="67"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>subjects</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="13"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="60"/>
                <measurement group_id="B2" value="63"/>
                <measurement group_id="B3" value="123"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>More than one race</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>FEV1, liters</title>
          <description>Forced Expiratory Volume in 1 second, liters</description>
          <units>liters</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="0.75" lower_limit="0.53" upper_limit="1.32"/>
                <measurement group_id="B2" value="0.80" lower_limit="0.64" upper_limit="1.23"/>
                <measurement group_id="B3" value="0.79" lower_limit="0.57" upper_limit="1.24"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Indication for Lung Transplant</title>
          <description>Placebo Group: Treatment Group:
COPD: 35 33 Cystic Fibrosis: 11 12 IPF: 16 16 Sarcoid: 2 3 Other: 2 6</description>
          <units>subjects</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>COPD</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="35"/>
                <measurement group_id="B2" value="33"/>
                <measurement group_id="B3" value="68"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Idiopathic Pulmonary Fibrosis</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="16"/>
                <measurement group_id="B2" value="16"/>
                <measurement group_id="B3" value="32"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Cystic Fibrosis</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
                <measurement group_id="B2" value="12"/>
                <measurement group_id="B3" value="23"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Sarcoid</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="5"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Other</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="8"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>FVC, liters</title>
          <description>forced vital capacity</description>
          <units>liters</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="2.02" lower_limit="1.52" upper_limit="2.62"/>
                <measurement group_id="B2" value="1.89" lower_limit="1.49" upper_limit="2.32"/>
                <measurement group_id="B3" value="1.95" lower_limit="1.51" upper_limit="2.48"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>6MWD, feet</title>
          <description>the distance in feet a subject walks in 6 minutes</description>
          <units>feet</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="1168" lower_limit="946" upper_limit="1350"/>
                <measurement group_id="B2" value="1120" lower_limit="945" upper_limit="1380"/>
                <measurement group_id="B3" value="1155" lower_limit="945" upper_limit="1380"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Smoking History</title>
          <description>Placebo Treatment Past:44/66 49/70 Current: 0 0 No hx:22/66 21/70</description>
          <units>subjects</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>No Smoking History/Never Smoked (past or present)</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="22"/>
                <measurement group_id="B2" value="21"/>
                <measurement group_id="B3" value="43"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Past Smoking History: former smokers who quit</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="44"/>
                <measurement group_id="B2" value="49"/>
                <measurement group_id="B3" value="93"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Current Smoking</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Daily Supplemental Oxygen Use</title>
          <description>the number of subjects requiring supplemental daily oxygen through nasal canula or face mask.</description>
          <units>subjects</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Supplemental Oxygen use</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="53"/>
                <measurement group_id="B2" value="51"/>
                <measurement group_id="B3" value="104"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>No supplemental oxygen use</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
                <measurement group_id="B2" value="19"/>
                <measurement group_id="B3" value="32"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of CMV End Organ Disease</title>
        <description>The primary study end point was CMV end-organ disease determined by positive tissue immunostain or characteristic histopathology assessed for within 300 days post randomization.</description>
        <time_frame>over the course of 300 days after randomization</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intention to treat analysis was conducted.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Group</title>
            <description>Upon randomization at 3 months, patients discontinued Valganciclovir and received no CMV prophylaxis for the next 9 months (short course prophylaxis)</description>
          </group>
          <group group_id="O2">
            <title>Treatment Group</title>
            <description>Upon randomization at 3 months, patients remained on Valganciclovir for 9 additional months (extended course prophylaxis).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="66"/>
                  <measurement group_id="O2" value="70"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Incidence of CMV End Organ Disease</title>
            <description>The primary study end point was CMV end-organ disease determined by positive tissue immunostain or characteristic histopathology assessed for within 300 days post randomization.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of CMV Syndrome</title>
        <description>CMV clinical syndrome, with either positive serum PCR or positive culture for CMV from bronchoalveolar lavage and at least 2 of the following: fever, leukopenia, thrombocytopenia, elevated liver function test results malaise, reduction in pulmonary function (FEV1) greater than 20percent of baseline, or radiographic infiltrate consistent with CMV (all in the absence of other causes)</description>
        <time_frame>over the course of 300 days after randomization</time_frame>
        <safety_issue>No</safety_issue>
        <population>intention to treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Group</title>
            <description>Upon randomization at 3 months, patients discontinued Valganciclovir and received no CMV prophylaxis for the next 9 months (short course prophylaxis)</description>
          </group>
          <group group_id="O2">
            <title>Treatment Group</title>
            <description>Upon randomization at 3 months, patients remained on Valganciclovir for 9 additional months (extended course prophylaxis).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="66"/>
                  <measurement group_id="O2" value="70"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Incidence of CMV Syndrome</title>
            <description>CMV clinical syndrome, with either positive serum PCR or positive culture for CMV from bronchoalveolar lavage and at least 2 of the following: fever, leukopenia, thrombocytopenia, elevated liver function test results malaise, reduction in pulmonary function (FEV1) greater than 20percent of baseline, or radiographic infiltrate consistent with CMV (all in the absence of other causes)</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Any CMV Infection</title>
        <description>Inclusive of CMV syndrome, disease, or infection not meeting primary end point.</description>
        <time_frame>over the course of 300 days post randomization</time_frame>
        <safety_issue>No</safety_issue>
        <population>intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Group</title>
            <description>Upon randomization at 3 months, patients discontinued Valganciclovir and received no CMV prophylaxis for the next 9 months (short course prophylaxis)</description>
          </group>
          <group group_id="O2">
            <title>Treatment Group</title>
            <description>Upon randomization at 3 months, patients remained on Valganciclovir for 9 additional months (extended course prophylaxis).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="66"/>
                  <measurement group_id="O2" value="70"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Any CMV Infection</title>
            <description>Inclusive of CMV syndrome, disease, or infection not meeting primary end point.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="42"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biopsy Proven Acute Lung Rejection</title>
        <time_frame>over the course of 300 days of randomization</time_frame>
        <safety_issue>No</safety_issue>
        <population>intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Group</title>
            <description>Upon randomization at 3 months, patients discontinued Valganciclovir and received no CMV prophylaxis for the next 9 months (short course prophylaxis)</description>
          </group>
          <group group_id="O2">
            <title>Treatment Group</title>
            <description>Upon randomization at 3 months, patients remained on Valganciclovir for 9 additional months (extended course prophylaxis).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="66"/>
                  <measurement group_id="O2" value="70"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Biopsy Proven Acute Lung Rejection</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="22"/>
                  <measurement group_id="O2" value="15"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-CMV Infection</title>
        <description>non cmv opportunistic infections</description>
        <time_frame>over the course of 300 days after randomization</time_frame>
        <safety_issue>No</safety_issue>
        <population>intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Group</title>
            <description>Upon randomization at 3 months, patients discontinued Valganciclovir and received no CMV prophylaxis for the next 9 months (short course prophylaxis)</description>
          </group>
          <group group_id="O2">
            <title>Treatment Group</title>
            <description>Upon randomization at 3 months, patients remained on Valganciclovir for 9 additional months (extended course prophylaxis).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="66"/>
                  <measurement group_id="O2" value="70"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Non-CMV Infection</title>
            <description>non cmv opportunistic infections</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                  <measurement group_id="O2" value="38"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Viremia</title>
        <description>upon diagnosis of cmv disease, the number of CMV DNA copies/mL as measured by PCR</description>
        <time_frame>over the course of 300 days after randomization</time_frame>
        <safety_issue>No</safety_issue>
        <population>intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Group</title>
            <description>Upon randomization at 3 months, patients discontinued Valganciclovir and received no CMV prophylaxis for the next 9 months (short course prophylaxis)</description>
          </group>
          <group group_id="O2">
            <title>Treatment Group</title>
            <description>Upon randomization at 3 months, patients remained on Valganciclovir for 9 additional months (extended course prophylaxis).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="66"/>
                  <measurement group_id="O2" value="70"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Severity of Viremia</title>
            <description>upon diagnosis of cmv disease, the number of CMV DNA copies/mL as measured by PCR</description>
            <units>CMV copies/mL</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="110000" lower_limit="40000" upper_limit="361569"/>
                  <measurement group_id="O2" value="3200" lower_limit="2700" upper_limit="3700"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ganciclovir Resistance</title>
        <description>UL97 genotyping was done on all positive samples for CMV DNA at 1000 copies/mL, with resistance defined by the presence of 1 or more mutations shown by marker transfer to confer phenotypic ganciclovir resistance</description>
        <time_frame>over the course of 300 days post randomization</time_frame>
        <safety_issue>No</safety_issue>
        <population>intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Group</title>
            <description>Upon randomization at 3 months, patients discontinued Valganciclovir and received no CMV prophylaxis for the next 9 months (short course prophylaxis)</description>
          </group>
          <group group_id="O2">
            <title>Treatment Group</title>
            <description>Upon randomization at 3 months, patients remained on Valganciclovir for 9 additional months (extended course prophylaxis).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="66"/>
                  <measurement group_id="O2" value="70"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Ganciclovir Resistance</title>
            <description>UL97 genotyping was done on all positive samples for CMV DNA at 1000 copies/mL, with resistance defined by the presence of 1 or more mutations shown by marker transfer to confer phenotypic ganciclovir resistance</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the first day posttransplant to the close of the study (day 390); however they were stratified by Phases (I and II) therefore SAEs are only reported for phase II subjects (ie only randomized subjects).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo Group</title>
          <description>Upon randomization at 3 months, patients discontinued Valganciclovir and received no CMV prophylaxis for the next 9 months (short course prophylaxis)</description>
        </group>
        <group group_id="E2">
          <title>Treatment Group</title>
          <description>Upon randomization at 3 months, patients remained on Valganciclovir for 9 additional months (extended course prophylaxis).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC STROKE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>CARDIAC DISORDERS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Hospitalization</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM DIFFICILE COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL DISORDERS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE RESPIRATORY DISTRESS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>BRONCHOSTENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>MULTI-ORGAN FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>LUNG TRANSPLANT REJECTION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>TRANSPLANT REJECTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>CYTOMEGALOVIRUS COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>LUNG INFILTRATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Opportunistic Infections, all organ systems</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Opportunistic Infections, all organ systems, mild</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Opportunistic Infections, all organ systems, moderate</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Opportunistic Infections, all organ systems, severe</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>PULMONARY HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>VISION BLURRED</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GASTROINTESTINAL DISORDERS</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>ABDOMINAL DISTENSION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>LUNG TRANSPLANT REJECTION</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>TRANSPLANT REJECTION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>WEIGHT INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>PULMONARY FUNCTION TEST DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>HEPATIC ENZYME INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>BREATH SOUNDS ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>HYPOMAGNESAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>MUSCULAR WEAKNESS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>TREMOR</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>MIGRAINE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>SINUS HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>DYSPNOEA EXERTIONAL</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>PRODUCTIVE COUGH</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>RHINORRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>WHEEZING</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>LUNG INFILTRATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>BRONCHOSTENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>CHEST DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>GENERALISED OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Scott M. Palmer, MD, MHS</name_or_title>
      <organization>Duke Clinical Research Institute</organization>
      <phone>919 684 0254</phone>
      <email>scott.palmer@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
